Four minute walk from the east exit of Ikebukuro Station (JR Line / Tokyo Metro Marunouchi Line, Yurakucho Line, Fuku-Toshin Line / Seibu Ikebukuro Line / Tobu Tojo Line)
History
2017.9
Founding of AI Medical Service, Inc.
2018.1
Developed the world’s first AI for gastric cancer detection using still images
2018.8
Raised funds during a series A round
2019.1
Developed the world’s first AI for esophageal detection using still images
2019.3
Developed the world’s first AI for esophageal detection using videos
2019.10
Raised funds during a series B round
2019.11
Received designated breakthrough device designation from the U.S. Food and Drug Administration (FDA) for our endoscopic system
2020.2
Awarded “EY Innovative Startup 2020”
2020.4
Demonstrated that AI for gastric cancer detection significantly outperforms endoscopists in terms of sensitivity
2020.4
Awarded “Fifth JEITA Venture Award”
2020.8
Relocated our headquarters to Hareza Tower
2020.10
Awarded Grand Prix in the Co-Creation PARK section on “CEATEC AWARD 2020”
2021.1
Demonstrated that endoscopists using AI during review of esophageal cancer videos results in increased sensitivity without decreasing specificity
2021.1
Selected for the “Innovation TOKYO Project” by the Bureau of Industrial and Labor Affairs of the Tokyo Metropolitan Government
2021.1
Designated as "Google for Startups Accelerator Class 3" by Google
2021.4
Finalized a joint research agreement with The National University Hospital, Singapore
2021.5
Launched "gastro AI Online,” a resource for the latest information in endoscopic AI
2021.6
Designated a “Technology Pioneer” by the World Economic Forum
2021.7
Received confirmation that our products comply with the IEC62304 and IEC62366-1 standards for medical devices
2021.8
Applied for regulatory approval for our first product, a device that supports doctors in the classification of gastric cancer
2021.10
Selected as a "J-Startup company" expected to expand business globally
2022.1
Established a US branch in Silicon Valley as a first global base
2022.5
Raised funds during a series C round from Softbank Vision Fund 2 etc.
2022.7
Established a Singapore branch as a second global base
2023.1
Established a US branch in New York as a second US base
2023.12
Obtained manufacturing and marketing approval for Endoscopic Diagnosis Support Software gastroAI model-G in Japan
2024.2
Completed regulatory review and device registration of Endoscopic Image Diagnosis Support Software - gastroAI-model G in Singapore
2024.12
Obtained manufacturing and marketing approval for Endoscopic Diagnosis Support Software gastroAI model-G2 in Japan
2025.06
Obtained medical device approval for Endoscopic Image Diagnosis Support Software - gastroAI-model G in Thailand
AI Medical Service by the numbers
Funding Amount (B Yen)
Employee Composition
Number of Countries※Contact with medical institution settled or under negotiation
HQ/Branch: Tokyo, New York, Singapore
Board Members
Tomohiro TadaRepresentative Director, Chief Medical Officer
Dr Tomohiro TADA is the Chairman of AI Medical Service Inc., the founder of Tada Tomohiro The Institute of Gastroenterology & Proctology, and Visiting Lecturer, Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo Hospital. Dr TADA received his M.D. from The University of Tokyo School of Medicine in 1996 and Ph.D. in 2005 from The University of Tokyo Graduate School of Medicine, Department of Surgical Sciences. He trained in Colorectal Surgery at The University of Tokyo Hospital.
Clinical Specialty Gastrointestinal Endoscopy
BOARD CERTIFICATION Japan Gastroenterological Endoscopy Society, Board Certified Fellow Japan Society of Gastroenterology FJGES （Fellow of Japan Gastroenterological Endoscopy Society） Japanese Gastroenterological Association
Yasushi TakigawaRepresentative Director
Graduated from the College of Economics at Kobe University and earned an MBA from the Graduate School of Management at Clark University in the United States. Began his career at Sumitomo Bank (now Sumitomo Mitsui Banking Corporation), where he served for 15 years. Later joined JMS Co., Ltd., where he established JMS North America Corporation and was appointed as an Executive Officer at the company’s headquarters. In 2008, founded the consulting firm Wedge Partners LLC. In 2009, led the commercialization of kidney disease diagnostic biomarkers at CMIC Co., Ltd. In 2011, co-founded Otsuka Medical Devices Co., Ltd. and served as Executive Vice President. Joined Boston Scientific Japan K.K. in 2015, where he oversaw Business Development in the endoscopy and CRM divisions, eventually serving as Executive Vice President and Head of Business Development for the Asia-Pacific region. Appointed President and Representative Director of Genesis MedTech Japan K.K. in 2022. In 2024, became a Partner in charge of the healthcare sector at RBG Partners, Inc.
Keisuke Tomiyasu Chief Technology Officer
Ph.D. in physics research. He engaged in research integrating experiments and data analysis at universities and UK facilities, and achieved 70 papers in English and more than 100 presentations at conferences. As Deputy Director of Research Laboratories at FRONTEO, he successfully led a major renewal of AI KIBIT, product implementation, and operational reforms.
Akitoshi YoshiokaChief Financial Officer
After working at the audit corporation Tohmatsu (currently Deloitte Touche Tohmatsu, LLC), he joined PKSHA Technology Inc. There, he lead the company to a listing on the TSE Mothers market as director and general manager of the business management division,
Kenichi Ikawa Chief Human Resources Officer
Kenichi Ikawa began his career in a sales role at a trading company before transitioning to HR in 2001. After gaining experience as an HR consultant, he led initiatives such as leadership development, the establishment of HRBP functions, the integration of HR infrastructure and the global standardization of HR systems at healthcare companies including Johnson & Johnson and Olympus.
Tadashi Idei Chief Regulatory & Quality Officer
Tadashi Idei has been in charge of regulatory affairs, clinical development, and quality assurance at several companies (domestic and foreign capital) engaged in the manufacture, import, and sales of medical devices. Prior to assuming his current position, he served as Board Director and head of the Regulatory Affairs Division at Japan Lifeline Co., Ltd.,
Yuma Endo Head of Product Development Department
Yuma Endo has extensive experience in the design and development of software products, ranging from devices to web applications. Previously, he served as he served as a lead engineer at a major domestic camera manufacturer, responsible for numerous software design and implementation projects. He joined AI Medical Service as a founding member in 2017.
Takashi HamadaOutside Corporate Auditor
Takashi Hamada is a certified public accountant, appointed as a member of the Audit and Supervisory Committee of the AI Medical Service in 2019. Previously, he was engaged in accounting audits, internal control construction support, IPO support, and financial accounting advisory at a major audit corporation.
Jun YokohamaOutside Director
Graduated from the University of Tokyo, Faculty of Economics, and the University of Chicago Booth School of Business, USA. After working for The Hokkaido Takushoku Bank, Ltd., Partner of Boston Consulting Group, Senior Executive Officer of Fast Retailing Co., Ltd., and President and CEO of Bushu Pharmaceuticals, he became an Executive Officer of Ryohin Keikaku Co., Ltd. He has extensive management experience and has been an outside director of AI Medical Service Inc., since November 2021.
Satoshi FukushimaOutside Director
Satoshi Fukushima was appointed as an outside director of this Company. He joined Globis Capital Partners & Co. in 2014. Prior to joining Globis, he engaged in M&A advisory and financing at the Deutsche Securities Inc and Investment Banking Headquarters. He earned a master’s degree in Economics at the University of Tokyo.
Masataka MatsumotoOutside Director
Masataka Matsumoto joined as the outside director of the AI Medical Service in 2019. Previously, he collaborated with other businesses to set up many joint ventures, founding WiL in 2013. He founded PIM Corporation in 1999 and as CEO directed its merger with Yahoo! JAPAN in 2000.
Hiroshi SensakiOutside Director
Graduated from the University of Tokyo (BA in Economics). He was engaged in principal investments at the Asian Special Situations Group of Goldman Sachs Tokyo. After founding startups and managing companies overseas, he joined SoftBank Group in 2019, and SoftBank Investment Advisers (Vision Fund) in 2022. He was appointed as an outside director of the Company in May 2022.
Yusuke MurataOutside Director
Yusuke Murata was appointed as an officer in 2018, and also has been an investor in AIM since its inception. In 2017, he received No. 1 ranking on Forbes Japan's "Ranking of the Most Influential Venture Investors in Japan.” He established Incubate Fund in 2010.
Hidekazu SuzukiOutside Corporate Auditor
After serving as an outside director and corporate auditor of several companies, Hidekazu Suzuki became a director and member of AI Medical Service’s audit and supervisory committee in 2018. He was president of Arbeit-Times Co., Ltd.
